Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 4/20 | 0.39 |
| ▸ | FAP | Q12884 | 4/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19143407 | 1.00 | HPGD (0.47) | HPGDSMN1; SMN2GAAKMT2AMAPK1 | |
| SCHEMBL26786294 | 0.93 | HPGD (0.45) | HPGDSMN1; SMN2GAAKMT2AMAPK1 | |
| SCHEMBL18731290 | 0.85 | CNR1 (0.43) | HPGDSMN1; SMN2GAAKMT2AMAPK1 | |
| SCHEMBL16254979 | 0.83 | CNR1 (0.47) | HPGDSMN1; SMN2GAAKMT2AMAPK1 | |
| SCHEMBL24067460 | 0.79 | ALDH1A1 (0.48) | HPGDKMT2AALDH1A1MEN1RAB9A | |
| SCHEMBL20038765 | 0.79 | EPHX1 (0.38) | HPGDKMT2AALDH1A1DPP4FAP | |
| SCHEMBL7542036 | 0.77 | POLB (0.59) | HPGDKMT2AALDH1A1MEN1CHRM2 | |
| SCHEMBL7542043 | 0.77 | POLB (0.59) | HPGDKMT2AALDH1A1MEN1CHRM2 | |
| SCHEMBL14218669 | 0.77 | HPGD (0.47) | HPGDSMN1; SMN2GAAKMT2AMAPK1 | |
| SCHEMBL13674784 | 0.77 | HPGD (0.47) | HPGDSMN1; SMN2GAAKMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218669-A1 | AUGMENTING ANTIGEN-NEGATIVE CELL DEATH IN ANTIGEN-TARGETED IMMUNOTHERAPIES | FRED HUTCHINSON CANCER CENTER (US) | 2023-07-13 | — | — | US | disclosed |
| US-11358950-B2 | SMAC mimetics used as IAP inhibitors and use thereof | CHIA TAI TIANGQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20210371400-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
| WO-2021148396-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371400-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | BIRC7, BIRC5, BIRC2 | HPGD 3229/4885SMN1; SMN2 419/4885GAA 1183/4885 |
| US-20230218669-A1 | AUGMENTING ANTIGEN-NEGATIVE CELL DEATH IN ANTIGEN-TARGETED IMMUNOTHERAPIES | CD47, BAD, CD74 | HPGD 3254/4885SMN1; SMN2 602/4885GAA 511/4885 |
| US-11358950-B2 | SMAC mimetics used as IAP inhibitors and use thereof | BIRC7, BIRC5, BIRC2 | HPGD 3229/4885SMN1; SMN2 419/4885GAA 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.